{"page":{"totalFilteredElements":84},"studies":[{"active":true,"description":"<div>R-Pola-Glo &#8211; A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R-CHOP</div>","eudractNumber":"2022-003398-51","id":8351,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD20","id":"mt_77"}],"nctNumber":"NCT05798156","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-01-02T14:56:14+01:00","shortTitle":"R-Pola-Glo","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR&#8217;S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)</div>","eudractNumber":"2022-502660-20","id":9250,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06091254","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-12-10T09:10:35+01:00","shortTitle":"R1979-HM-2298 (OLYMPIA-1)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<p>An Open-Label Study to Assess the Anti-Tumor Activity and Safety of \nREGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With \nRelapsed or Refractory B-cell Non-Hodgkin Lymphom\n            </p>","eudractNumber":"2017-002139-41","id":3873,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT03888105","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2020-08-25T14:49:57+02:00","shortTitle":"R1979-ONC-1625","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A&#160;Retrospective, Multicountry Study of Clinical Outcomes in Patients with Relapsed/ Refractory Multiple Myeloma Treated with T-cell Redirectors Outside of Clinical Trials (REALiTEC)<br /><div>\n  64007957MMY4004\n  [REALiTEC]</div>","eudractNumber":null,"id":8882,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06285318","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-05-01T10:04:17+02:00","shortTitle":"REALiTEC","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Registerplattform H&#228;matologische Neoplasien (RUBIN) - Erweiterung des Tumorregisters Lymphatische Neoplasien","eudractNumber":null,"id":10683,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06043011","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":null,"shortTitle":"RUBIN","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prospective study with continuous and fixed-Duration Ibrutinib based First Line Treatment in patients with Chronic Lymphocytic Leukemnia in real world setting","eudractNumber":null,"id":9253,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-03-03T13:01:22+01:00","shortTitle":"Reality 2","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Retentionsrate von Acalabrutinib in einem nicht-interventionellen Setting","eudractNumber":null,"id":10601,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05645172","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-01-05T09:26:40+01:00","shortTitle":"Retain","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A non-interventional study of selinexor (Nexpovio) in combination with bortezomib and dexamethasone (SVd) in patients with relapsed or refractory multiple myeloma (R/RMM) - SEATTLE -","eudractNumber":null,"id":11163,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-02-01T14:17:05+01:00","shortTitle":"SEATTLE","therapeutical":false,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"A non-interventional study of selinexor (Nexpovio) in combination with bortezomib and dexamethasone (SVd) in patients with relapsed or refractory multiple myeloma (R/RMM) - SEATTLE - <br />","eudractNumber":null,"id":8881,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-05-22T14:57:51+02:00","shortTitle":"SEATTLE","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p class=\"MsoNormal\">A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)</p><p class=\"MsoNormal\"><b>CA057-001</b></p>","eudractNumber":"2023-509859-13","id":10285,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05519085","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-03-13T15:17:15+01:00","shortTitle":"SUCCESSOR-1","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"}]}]}